CSL will pay Alentis $355 million upfront to co-develop lixudebart for rare kidney and liver diseases, with up to $1.2 ...

A new narrative review maps the psychiatric comorbidities behind dermatitis artefacta and argues that empathetic, integrated ...

In an infusion bay at UPMC Children’s Hospital of Pittsburgh, Billy Ellsworth twists the plastic top off of a bottle of Gatorade. “That was kind of tough, to be honest,” he said. “I wasn’t sure I was ...

A suspected pneumonic plague case in Russia has left nearly 200 people under medical observation after a 27-year-old ...

Taiwan-listed emerging biotech AnnJi (7754.TW) announced that its lead drug candidate AJ201 has received clearance from the U.S. Food and ...

A Telford man living with a rare type of blood cancer kicked off the town’s latest parkrun to publicise his four-year search ...

The number of treatments for rare genetic disorders is expected to increase sharply in the next several years.

CSL Limited (ASX:CSL) has secured an exclusive licensing agreement with Swiss biotechnology company Alentis Therapeutics to develop and commercialise lixudebart, an experimental treatment targeting ...

The family of a 13-year-old boy from Long Beach is asking for help as he remains hospitalized with a rare disease linked to ...

Investing.com-- CSL Ltd (ASX:CSL) shares rose on Monday after the Australian healthcare company said it had agreed to pay up to $1.6 billion to jointly develop and commercialise an experimental ...

"Our aim would be to get leaflets out into the wider community and say 'look, if this person looks drunk, faints or falls, ...

CSL (ASX:CSL) has ramped up its research and development efforts via a US$355 million ($515m)-plus drug development collab ...